Lorlatinib for ALK-positive advanced non-small-cell lung cancer that has not been treated with an ALK inhibitor

Equality impact assessment (guidance development) (PDF 124 KB)

TA 909 Final scope (PDF 169 KB)

TA909 Final stakeholder list (PDF 184 KB)

TA909 Draft consultation document (downloadable version) (PDF 382 KB)

TA909 DG Committee papers (PDF 6.88 MB)

TA909 Final Draft Guidance (PDF 416 KB)

TA909 FDG Committee papers (PDF 1.19 MB)

Final draft guidance

Final draft guidance (PDF 277 KB)

Public committee slides (PDF 742 KB)

Committee papers (PDF 2.19 MB)

Draft guidance

Draft guidance (downloadable version) (PDF 273 KB)

Committee papers (PDF 7.02 MB)

Equality impact assessment (downloadable version) (PDF 102 KB)

Public committee slides (PDF 758 KB)

Final scope (PDF 176 KB)

NICE's response to comments on the draft scope and provisional stakeholder list (PDF 137 KB)

Equality impact assessment (scoping) (PDF 124 KB)

Review proposal consultation

Review proposal paper (MSWord 40 KB)